Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.10 Average PT from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given a consensus rating of “Buy” by the eleven analysts that are presently covering the firm, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $57.10.

MIRM has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners raised their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Citigroup increased their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Mirum Pharmaceuticals Stock Down 1.6 %

Shares of MIRM opened at $41.32 on Thursday. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -20.46 and a beta of 0.98. The business’s 50 day simple moving average is $42.95 and its 200-day simple moving average is $40.72. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same quarter in the prior year, the firm posted ($0.57) EPS. Mirum Pharmaceuticals’s quarterly revenue was up 89.4% compared to the same quarter last year. As a group, equities analysts expect that Mirum Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the transaction, the chief executive officer now directly owns 119,359 shares in the company, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jolanda Howe sold 750 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the sale, the senior vice president now directly owns 2,926 shares of the company’s stock, valued at approximately $125,291.32. This represents a 20.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,737 shares of company stock worth $556,098 in the last ninety days. 22.87% of the stock is owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares in the last quarter. Amalgamated Bank boosted its position in Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares in the last quarter. Arizona State Retirement System grew its holdings in Mirum Pharmaceuticals by 10.6% in the second quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock valued at $315,000 after purchasing an additional 883 shares during the last quarter. Quest Partners LLC increased its position in shares of Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after buying an additional 1,127 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in shares of Mirum Pharmaceuticals by 17.1% during the 2nd quarter. Commonwealth Equity Services LLC now owns 14,050 shares of the company’s stock worth $480,000 after buying an additional 2,050 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.